News >

Avelumab Misses Primary Endpoints in Phase III Ovarian Cancer Trial

Gina Columbus @ginacolumbusonc
Published: Monday, Nov 19, 2018

Alfred Sackeyfio
Avelumab (Bavencio) alone or in combination with pegylated liposomal doxorubicin (PLD) did not induce a statistically significant improvement in overall survival (OS) or progression-free survival (PFS) versus PLD alone in patients with platinum–resistant/refractory ovarian cancer, missing the primary endpoints of the phase III JAVELIN Ovarian 200 trial.

Moreover, JAVELIN Ovarian PARP 100 (NCT03642132) is an open-label, multicenter, phase III study randomizing patients with previously untreated advanced ovarian cancer to avelumab plus platinum-based chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib (Talzenna); chemotherapy followed by maintenance therapy with talazoparib; or chemotherapy plus bevacizumab (Avastin), followed by bevacizumab maintenance.
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer. Merck KGaA and Pfizer. Published November 19, 2018.. Accessed November 19, 2018. https://bit.ly/2PGGzPB.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x